NHS England is set to introduce a pioneering liquid biopsy blood test, offering new hope to lung and breast cancer ...

People with lung cancer will be offered a new blood test designed to speed up access to targeted treatments and avoid ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

A new "liquid biopsy" test can help fast-track lung cancer patients to receive targeted therapy up to two weeks earlier, ...

Discover the NHS’s new pioneering "liquid biopsy" blood test for patients with cancer across England. Learn more.

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

The new "liquid biopsy" test searches for tiny fragments of DNA that are shed by tumours into the bloodstream - it can ...

The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

A mother-of-two from Carlisle says she has been given her life back after receiving targeted cancer treatment.

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.